Package Leaflet: Information for the User
Rivaroxaban Teva 10 mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
This medication contains the active substance rivaroxaban and is used in adults for:
This medication belongs to a group of medications called antithrombotic agents. It works by blocking a clotting factor (factor Xa) and thus reducing the tendency of blood to form clots.
Do not take Rivaroxaban Teva
Do not take this medication and inform your doctor if any of these circumstances apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
Be careful with Rivaroxaban Teva
Tell your doctorif you have any of these conditionsbefore taking this medication. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If you need surgery:
Children and adolescents
Rivaroxaban 10 mg tablets are not recommended for children under 18 years of age.There is not enough information available on their use in children and adolescents.
Other medications and Rivaroxaban Teva
Tell your doctor or pharmacist if you are taking, have recently taken, or may take any other medication, including those obtained without a prescription.
If any of the above circumstances apply to you,tell your doctorbefore taking this medication, as the effect of rivaroxaban may be increased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing stomach or intestinal ulcers, they will recommend that you also use a preventive treatment for ulcers.
If you take:
If any of the above circumstances apply to you,tell your doctorbefore taking this medication, as the effect of rivaroxaban may be reduced. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
Pregnancy and breastfeeding
Do not take rivaroxaban if you are pregnant or breastfeeding. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking rivaroxaban. If you become pregnant while taking this medication, tell your doctor immediately, who will decide how you should be treated.
Driving and using machines
This medication may cause dizziness (a common side effect) or fainting (an uncommon side effect) (see section 4, "Possible side effects"). You should not drive, ride a bicycle, or use tools or machines if you are affected by these symptoms.
This medication contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially "sodium-free".
Follow the instructions for administration of this medication exactly as indicated by your doctor. If you are in doubt, consult your doctor or pharmacist again.
What doseto take
The recommended dose is one 10 mg rivaroxaban tablet once a day.
After at least 6 months of treatment for blood clots, the recommended dose is one 10 mg tablet once a day or one 20 mg tablet once a day. Your doctor has prescribed rivaroxaban 10 mg once a day.
Swallow the tablet, preferably with water.
Rivaroxaban can be taken with or without food.
If you have difficulty swallowing the tablet whole, consult your doctor about other ways to take rivaroxaban. The tablet can be crushed and mixed with water or apple puree, immediately before taking it.
If necessary, your doctor can also administer the crushed rivaroxaban tablet through a gastric tube.
When to take RivaroxabanTeva
Take one tablet every day, until your doctor tells you to stop.
Try to take one tablet at the same time every day, to help you remember.
Your doctor will decide how long you should continue taking the treatment.
To prevent the formation of blood clots in the veins after hip or knee replacement surgery:
Take the first tablet 6 to 10 hours after surgery.
If you have undergone major hip surgery, you will usually take tablets for 5 weeks.
If you have undergone major knee surgery, you will usually take tablets for 2 weeks.
If you take more RivaroxabanTevathan you should
Call your doctor immediately if you have taken too many rivaroxaban tablets. Taking too much rivaroxaban increases the risk of bleeding.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take RivaroxabanTeva
If you forget to take a dose, take it as soon as you remember. Take the next tablet the next day and, after that, take one tablet every day, as usual.
Do not take a double dose to make up for forgotten doses.
If you stop taking RivaroxabanTeva
Do not stop taking rivaroxaban without talking to your doctor first, as rivaroxaban prevents the development of a serious condition.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, rivaroxaban can cause side effects, although not everyone will experience them.
Like other similar medications to reduce blood clotting, rivaroxaban can cause bleeding, which can be life-threatening. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be visible.
Tell your doctor immediatelyif you experience any of the following side effects:
Your doctor will decide to keep you under closer observation or modify your treatment.
The frequency of this side effect is very rare (up to 1 in 10,000).
The frequencies of severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible side effects:
Common(may affect up to 1 in 10 patients):
Uncommon(may affect up to 1 in 100 patients):
Rare(may affect up to 1 in 1,000 patients):
Very rare(may affect up to 1 in 10,000 people)
Frequency not known(cannot be estimated from available data):
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are side effects not listed in this package leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the packaging and on each blister, after "CAD" or "EXP". The expiry date is the last day of the month indicated.
This medicine does not require any special storage conditions.
Crushed tablets
Crushed tablets are stable in water or apple puree for up to 4 hours.
Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medicine in the SIGRE collection point at your pharmacy. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Rivaroxaban Teva
Tablet core:sodium laurilsulfate, lactose monohydrate, hypromellose, sodium croscarmellose, and magnesium stearate.
Tablet coating:partially hydrolyzed polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol 3350, talc (E553b), carmine (E120), yellow iron oxide (E172), and red iron oxide (E172).
Appearance and packaging of the product
Rivaroxaban Teva 10 mg film-coated tablets are pink, round, approximately 8 mm in diameter, engraved with "T" on one side and "1R" on the other.
They are available in:
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Teva GmbH
Graf-Arco-Str. 3
Ulm, 89079
Germany
Manufacturer
Balkanpharma - Dupnitsa AD
3, Samokovsko Shosse Str.
BG-2600 DUPNITSA
Bulgaria
or
Actavis Group PTC ehf,
Dalshraun 1, Hafnarfjoerdur,
220, Iceland
Local representative
Teva Pharma, S.L.U.
C/Anabel Segura, 11 Edificio Albatros B, 1ª Planta
Alcobendas, 28108 Madrid
Spain
Date of last revision of this leaflet:November 2023
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
You can access detailed and updated information on this medicine by scanning the QR code included in the packaging with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/85818/P_85818.html